BICX - BioCorRx Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

BioCorRx Inc.

2390 East Orangewood Avenue
Suite 575
Anaheim, CA 92806
United States

IndustryMedical Care
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Brady James GranierPres, CEO & Director210kN/A1972
Ms. Lourdes FelixCFO, COO & Director199.05kN/A1968
Dr. Balbir S. BrarSr. VP of Drug Devel.N/AN/A1937
Dr. George N. FallierasMedical ConsultantN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. The company distributes and licenses BioCorRx recovery program, a medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant. It is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is headquartered in Anaheim, California.

Corporate Governance

BioCorRx Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.